Psilocybin Smoking Cessation: What the Research Shows

Why Is Psilocybin Being Studied for Quitting Smoking?

Most people who want to quit smoking already know the odds are against them. Nicotine is one of the most stubborn dependencies in medicine, and the numbers reflect it. Even the best available treatments, including varenicline and nicotine replacement, leave most smokers back at baseline within a year. Tobacco still causes roughly 480,000 deaths a year in the United States, which is more than any other addictive substance. Against that backdrop, a treatment that works differently is worth serious attention.

Psilocybin, the active compound in psilocybin mushrooms, entered this conversation for a specific reason. Researchers noticed that it seemed to help people change entrenched behavior, not by acting on nicotine receptors, but by changing something about the person’s relationship to the behavior. That distinction matters, and it is the core of why psilocybin smoking cessation research has drawn the interest it has.

What Did the Johns Hopkins Psilocybin Smoking Study Find?

The study that started this line of work was a small open-label pilot published in 2014 by Matthew Johnson and colleagues at Johns Hopkins. Fifteen long-term smokers took part. On average they had smoked around 19 cigarettes a day for 31 years and had made roughly six serious quit attempts before enrolling. These were not casual smokers looking for a nudge. They were people for whom quitting had repeatedly failed.

Each participant went through a structured 15-week program built around cognitive behavioral therapy, with psilocybin sessions layered in on a set quit date and at follow-up points. The results were striking. Twelve of the 15 participants, or 80%, were verified smoke-free at the six-month mark, confirmed not just by self-report but by breath and urine testing. A longer follow-up found that 67% were still abstinent at 12 months. For comparison, the most effective standard smoking medications typically produce abstinence rates below 35%.

A pilot study of this size cannot prove that psilocybin caused those outcomes. There was no control group, and the participants knew what they were taking. The researchers were careful to frame the findings as a signal worth pursuing, not a conclusion. Still, abstinence numbers of that magnitude after only two or three sessions are rare enough in addiction medicine to be hard to dismiss.

Did a Controlled Trial Confirm the Early Results?

This is where the research matured. In early 2026, the Johns Hopkins group published a randomized controlled trial in JAMA Network Open, the first study to compare psilocybin directly against an established treatment. Eighty-two smokers were randomized to receive either a single high dose of psilocybin or an 8-to-10-week course of the nicotine patch. Both groups received the same cognitive behavioral therapy program, so the therapy itself was held constant and the comparison isolated the medicine.

At the six-month follow-up, participants in the psilocybin group had more than six times the odds of sustained, biologically verified abstinence compared to those on the patch. In concrete terms, about 40% of the psilocybin group maintained prolonged abstinence, versus 10% of the patch group. No serious adverse events were attributed to either treatment. Because participants knew which treatment they received, the trial was not fully blinded, and the researchers describe it as a pilot rather than a definitive verdict. Even so, it moved the evidence from suggestive toward something more substantial.

How Does Psilocybin Actually Help Someone Quit?

This is the part that surprises people. Psilocybin does not work like a nicotine substitute. It does not occupy the receptors nicotine acts on, and it is not taken daily to blunt cravings. A person might have two or three guided sessions across several weeks and nothing more.

Once in the body, psilocybin converts to psilocin, which activates specific serotonin receptors concentrated in the prefrontal cortex, the part of the brain most involved in self-reflection, mood, and habit. What follows is a temporary window in which the brain becomes unusually flexible, more able to loosen fixed patterns and consider alternatives. Researchers connect this to the idea that deeply grooved behaviors, like reaching for a cigarette, can feel less automatic and less inevitable afterward.

The research also points to something less mechanical. In the Hopkins work, the participants who had the most profound subjective experiences during their sessions were the ones most likely to stay abstinent. Garcia-Romeu and colleagues found that the intensity of what participants described as a meaningful or transcendent experience predicted who quit and who did not. It was not the raw intensity of the drug effect that mattered, but the personal significance of the experience. People often described stepping outside the story they told themselves about being a smoker, and responding to cravings with a moment of choice rather than reflex.

This mechanism helps explain why psilocybin has shown similar promise across other addictions. The same pattern of results has appeared in research on psilocybin for alcohol use disorder, which points to a shared underlying process rather than an effect specific to tobacco.

What Do Real-World Reports Add to the Clinical Picture?

Clinical trials are controlled and small. To understand what happens outside the lab, the Hopkins team ran a survey of 358 people who reported quitting or cutting back on smoking after taking a psychedelic on their own, in non-clinical settings. On average these respondents had smoked for years and had failed several previous quit attempts.

Among them, 38% reported continuous abstinence after their psychedelic experience, and of those, most had stayed smoke-free for more than two years. Another 28% reported a lasting reduction, often dramatic, dropping from hundreds of cigarettes a month to almost none. A notable share, 34%, relapsed within months. What separated the two groups was telling. People who relapsed tended to rate their experience as far less personally meaningful. Across all groups, participants reported that withdrawal symptoms like irritability and low mood felt milder than in their previous attempts.

Survey data has real limits. People who quit are more motivated to respond, memories are imperfect, and there is no control group. But the naturalistic reports line up with the clinical findings in a way that strengthens the overall picture.

How Should Psilocybin Mushrooms Be Understood in This Context?

Because most people encounter psilocybin outside a research setting, it helps to be clear about what the substance actually is. The clinical trials used precise, pharmaceutical-grade psilocybin dosed by body weight, typically 20 to 30 mg per 70 kg. Outside the lab, psilocybin is almost always consumed as mushrooms, and that introduces real variability.

People encounter psilocybin in several forms: dried whole mushrooms, tea (mushrooms steeped in hot water, often with ginger to ease nausea), lemon tek (dried mushrooms soaked in lemon or lime juice, thought to speed onset), capsules of ground mushroom powder for more consistent dosing, and chocolates or edibles where dose consistency varies widely. The clinical forms are precise. The real-world forms are not.

Dosing is genuinely imprecise without a known source. As a rough guide, a low or threshold dose is around 1 to 2g of dried Psilocybe cubensis (roughly 7 to 14mg psilocybin), a moderate dose is 2 to 3.5g (roughly 14 to 25mg), and a full dose is 3.5 to 5g (roughly 25 to 35mg). These are approximations only. Potency varies significantly by strain, by individual specimen, and by storage conditions. Strain matters more than most people expect. Golden Teacher is moderate and widely used with beginners. B+ is moderate with a forgiving onset. Mazatapec is gentle and traditionally used in ceremony. Albino A+ runs moderate to high with a faster onset. Penis Envy contains substantially more psilocybin than most strains and is not a beginner’s mushroom. This range is exactly why weight alone tells you little without knowing the source.

What Are the Risks and Limits Worth Knowing?

Psilocybin has a favorable physical safety profile in supervised settings, but it is not risk-free, and it is not appropriate for everyone. A personal or family history of psychosis or bipolar disorder is a serious consideration, as are certain cardiac conditions and some medications. Anyone weighing this should first review the full picture of who should pause before pursuing psychedelic therapy.

The research context also matters enormously. Every positive result described here came from sessions with extensive psychological support, careful screening, and structured therapy wrapped around the experience. The medicine was never the whole intervention. The set and setting, the preparation, and the integration afterward all did real work. A high dose taken alone, without support, is a different situation with a different risk profile and no guarantee of the same benefit.

It is also worth being honest about the state of the evidence. These are small studies from a small number of research groups. The controlled trial was not fully blinded. Psilocybin remains illegal under federal law in the United States, with regulated therapeutic access currently limited to Oregon and Colorado. The science is genuinely encouraging, and it is also early.